01 NTRK基因重排在实体瘤中的广谱性 02 NTRK基因重排在实体瘤中的突变频率 03 NTRK基因融合的检测技术 04 NTRK 基因融合诊断策略 05 NTRK 基因融合抑制剂 参考文献 向上滑动阅览 1、NTRK gene fusions in solid tumors: agnostic relevance, prevalence and diagnostic strategies,PATHOLOGICA 2022;114:199-216; DOI: 10.32074/1591-951X-787. 2、Russo A, Incorvaia L, Malapelle U, et al. The tumor-agnostic treatment for patients with solid tumors: a position paper on behalfof the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientiffc Societies.Crit Rev Oncol Hematol 2021;165:103436. https:///10.1016/j.critrevonc.2021.103436. 3、Marchetti A, Di Lorito A, Felicioni L, et al. An innovative diagnosticstrategy for the detection of rare molecular targets to selectcancer patients for tumor-agnostic treatments. Oncotarget 2019;10:6957-6968. https:///10.18632/oncotarget.27343. PMID: 31857850; PMCID: PMC6916754. 4.Solomon JP, Linkov I, Rosado A, et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol 2020;33:38-46. https:///10.1038/s41379-019-0324-7. Epub 2019 Aug 2. PMID: 31375766; PMCID: PMC7437403. 5.Rosen EY, Goldman DA, Hechtman JF, et al. TRK fusions are enrichedin cancers with uncommon histologies and the absence of canonical driver mutations. Clin Cancer Res 2020;26:1624-1632. https:///10.1158/1078-0432.CCR-19-3165. Epub 2019 Dec 23. PMID: 31871300; PMCID: PMC7124988. 6.Rosen EY, Goldman DA, Hechtman JF, et al. TRK fusions are enrichedin cancers with uncommon histologies and the absence of canonical driver mutations. Clin Cancer Res 2020;26:1624-1632. https:///10.1158/1078-0432.CCR-19-3165. Epub 2019 Dec 23. PMID: 31871300; PMCID: PMC7124988. 7.Gatalica Z, Xiu J, Swensen J, et al. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol 2019;32:147-153. https:///10.1038/s41379-018-0118-3. Epub 2018 Aug 31. PMID: 30171197. 8.Westphalen CB, Krebs MG, Le Tourneau C, et al. Genomic contextof NTRK1/2/3 fusion-positive tumours from a large real-world population. NPJ Precis Oncol 2021;5:69. https:///10.1038/s41698-021-00206-y. PMID: 34285332; PMCID: PMC8292342. END |
|
来自: remember草木 > 《分子临床病理》